36
Management
Table 12. Crosswalk Between 10-Year Risk ASCVD Estimates
From PCE and PREVENT-ASCVD Equations
Approximate Equivalent Ranges of 10-Year ASCVD Risk
Estimates*
Risk Group PCE PREVENT-ASCVD
Low <5% <3%
Borderline 5%–<7.5% 3% to <5%
Intermediate 7.5%–<20% 5% to <10%
High ≥20% ≥10%
* e PREVENT-ASCVD equations generally provide 10-year risk estimates that are 40% to
50% lower than the PCE estimates because the PCE calculator oen overestimated the risk
for adults.
ASCVD denotes atherosclerotic cardiovascular disease; and PCE, pooled cohort equations.
Adapted from Khan et al.
4.2.3.3. Risk Enhancers
COR LOE
Recommendations
2a B-NR
1. In adults without ASCVD with a borderline 10-year ASCVD
risk estimate (3% to <5%) by the PREVENT-ASCVD
equations, consideration of risk enhancers is reasonable
to personalize risk assessment and the potential benefit of
initiating LLT as an adjunct to lifestyle management to
reduce ASCVD risk (Table 13).
2a B-R
2. In adults without ASCVD with a borderline 10-year
ASCVD risk estimate (3% to <5%) by the PREVENT-
ASCVD equations, if high-sensitivity C-reactive protein
(hsCRP) is measured and is ≥2 mg/L on 2 successive
occasions with no identifiable underlying cause of hsCRP
elevation, high-intensity statin therapy can be useful to
reduce the risk of ASCVD events.
